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Abstract 
The thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are well established 
agents for the treatment of leukaemia but their main modes of action are controversial. 
Thiopurine methyltransferase (TPMT) metabolizes thiopurine drugs and influences their 
cytotoxic activity. TPMT, like DNA methyltransferases (DNMTs), transfers methyl groups 
from S-adenosylmethionine (SAM) and generates S-adenosylhomocysteine (SAH). Since 
SAM levels are dependent on de novo purine synthesis (DNPS) and the metabolic products of 
6-TG and 6-MP differ in their ability to inhibit DNPS, we postulated that 6-TG compared to 
6-MP would have differential effects on changes in SAM and SAH levels and global DNA 
methylation, depending on TPMT status. To test this hypothesis, we used a human embryonic 
kidney cell line with inducible TPMT. Although changes in SAM and SAH levels occurred 
with each drug, decrease in global DNA methylation more closely reflected a decrease in 
DNMT activity. Inhibition was influenced by TPMT for 6-TG, but not 6-MP. The decrease in 
global methylation and DNMT activity with 6-MP, or with 6-TG when TPMT expression was 
low, were comparable to 5-aza-2’-deoxycytidine. However, this was not reflected in changes 
in methylation at the level of an individual marker gene (MAGE1A). The results suggest that a 
non-TPMT metabolised metabolite of 6-MP and 6-TG and the TPMT-metabolised 6-MP 
metabolite 6-methylthioguanosine 5’-monophosphate, contribute to a decrease in DNMT 
levels and global DNA methylation. As demethylating agents have shown promise in 
leukaemia treatment, inhibition of DNA methylation by the thiopurine drugs may contribute 
to their cytotoxic affects.  
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1  Introduction 
The methylation of cytosine bases in DNA is an important mechanism regulating gene 
expression. The discovery that most cancers have aberrant DNA methylation involving 
hypermethylation of gene promoters, often associated with silencing of tumour suppressor 
and growth inhibitory genes [1], has led to interest in therapeutic agents which can reduce 
DNA methylation [2-5]. The azanucleosides, 5-azacytidine and 5-aza-2’deoxycytidine (5-
AdC/decitabine), inhibit the DNA methyltransferases (DNMTs) responsible for methylating 
DNA [6-8] and have shown particular promise in the treatment of haematological 
malignancies [9, 10]. DNMTs utilise S-adenosylmethionine (SAM) as a methyl donor for the 
methylation of cytosine bases in DNA, with the subsequent conversion of SAM to S-
adenosylhomocysteine (SAH) [11]. Several studies have shown that alterations in the levels 
of SAM and SAH, and in particular the ratio of SAM to SAH, relate to changes in DNA 
methylation [12-14], as SAH has an inhibitory affect on DNMT activity [15].  
The thiopurine drugs, 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used 
extensively in the treatment of acute leukaemias [16, 17]. Although there are similarities in 
their metabolism (Fig. 1), the cytotoxicity of these drugs in vitro is differentially affected by 
the level of expression of thiopurine methyltransferase (TPMT) [18, 19]. This enzyme has 
widely varying activity between individuals, predominantly due to single nucleotide 
polymorphisms [20, 21]. An effect of the thiopurine drug, 6-MP, and 6-methyl-
mercaptopurine riboside (rMeMP) on DNA methylation has been described in the T-cell acute 
lymphoblastic leukaemic (T-ALL) cell line MOLT-4 [22-24]. Both 6-MP and rMeMP (an 
analogue of adenosine) inhibited de novo purine synthesis (DNPS), via a common metabolite 
6-methylthioinosine 5’-monophosphate (MeTIMP) [25, 26],and consequently caused a 
decrease of adenosine triphosphate (ATP). The depletion of ATP, as a precursor of SAM, was 
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thought to result in the depletion of SAM and decreased DNA methylation observed in the 
MOLT-4 cell line exposed to 6-MP [22]. 
Since levels of TPMT in cells treated with thiopurine drugs influence the extent of DNPS 
inhibition [18, 19], DNA methylation and changes in the SAM/SAH ratio may also be 
influenced by TPMT. Given that the TPMT-catalysed metabolic product of 6-TG, 6-
methylthioguanine 5’-monophosphate (MeTGMP), is a much weaker inhibitor of DNPS than 
MeTIMP produced from 6-MP [27], we postulated that 6-TG would have a reduced effect 
compared to 6-MP on changes in SAM and SAH levels and global DNA methylation. To test 
these hypotheses, we used a previously generated human embryonic kidney cell line in which 
human TPMT cDNA is inducibly-expressed under the control of an ecdysone promoter [19]. 
We show that both 6-MP and 6-TG reduced global DNA methylation in these cells and that 
decreases in DNMT activity, rather than changes in SAM and SAH levels, may be the 
overriding mechanism. Alterations in global DNA methylation and DNMT activity were 
TPMT dependent only when the cells were treated with 6-TG.  
 
2.  Materials and Methods 
2.1  Chemicals 
Chloroacetaldehyde, SAM, SAH, 6-MP, 6-TG, rMeMP, Nuclease P1, ribonuclease A (from 
bovine pancreas), deoxyribonuclease 1 (DNase 1), and propidium iodide were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). All other chemicals were purchased from Sigma-Aldrich, 
Fischer Scientific UK Ltd (Leicestershire, UK), VWR International (Leicestershire, UK) or 
Roche (Lewes, UK) unless otherwise stated. 
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2.2  Cell culture and induction of TPMT 
Human embryonic kidney cells containing the pVgRXR vector (EcR293) were transfected 
with pIND vector containing human TPMT cDNA (EcR293-TPMT/20) and maintained as 
previously described within our laboratory [19]. The EcR293 cells were maintained in the 
similar way, but medium was supplemented only with the antibiotic for maintaining selection 
of the pVgRXR vector. TPMT expression in EcR293-TPMT/20 cells was induced with 3 µM 
Muristerone A (MA) (Invitrogen Ltd, Paisley, UK) dissolved in ethanol, for 24 hours prior to 
48 hour exposure of cells to 6-MP, 6-TG, rMeMP or 5-AdC. Control cells were treated with 3 
µL/mL ethanol alone. For MAGE1A gene promoter analysis cells were treated with drugs for 
6 doubling times (174 hours for MA-induced cells and 126 hours for ethanol-treated control 
cells). The parental EcR293 cells were treated with MA or ethanol control in the same way. 
After drug treatments cells were harvested, washed twice with PBS and cell pellets snap 
frozen in liquid nitrogen and then stored at -80°C prior to analysis. 
 
2.3  MeTIMP levels 
MeTIMP levels were measured as described by Coulthard et al [19]. Briefly, pellets of 5 x 106 
cells were re-suspended in 500 µL Tris-EDTA buffer (10mM Tris-HCl, pH 8.0, 1mM EDTA) 
and sonicated for 20 seconds. A 100 µL aliquot was removed for total protein estimation 
using the BCA kit as described in the manufacturer’s instuctions (Perbio Science Ltd, 
Cramlington, UK). Remaining lysate was filtered using a Centrikon-3K filter (Millipore, 
Bedford, MA) at 20,800g for 45 minutes and MeTIMP measured in the filtrate by HPLC, as 
described by Krynetski et al [28]. MeTIMP concentration was expressed per mg total protein. 
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2.4  SAM and SAH levels 
Sample preparation for the measurement of SAM and SAH levels was based on a method by 
Shugart [29]. Pellets of approximately 5x106 cells were lysed in 0.3 mL ice-cold water by 
sonication for 5 seconds at 10 µm. To 180 µL of lysate or SAM/SAH standards (4 µM to 0.03 
µM) prepared in water, 20 µL of 40% TCA was added, vortexed, and incubated on ice for 30 
minutes. The remaining lysate was used for total protein estimation as described above. After 
30 minutes the samples and standards were centrifuged at 20800g for 10 minutes at 4 oC. To 
150 µL of cell lysates and standards, 150 µL of 2M sodium acetate buffer pH 4.5 and 120 µL 
of 12% (v/v) chloroacetaldehyde was added, followed by incubation at 60°C for 1 hour. 
Samples were then centrifuged at 20800g for 10 minutes at room temperature and fluorescent 
SAM and SAH chloroacetaldehyde derivatives were analysed by HPLC. One hundred µL of 
sample was injected into a Waters HPLC system (Waters, Elstree, UK) equipped with a 
Synergi 4µm Hydro RP 80Ǻ 250 x 4.6mm column (Phenomenex, Macclesfield, UK) with an 
AQ-C18 4 x 3mm guard column (Phenomenex) maintained at 30oC, a refrigerated (4oC) 
sample chamber, and a 980 programmable fluorescence detector (Applied Biosystems, 
Warrington, UK) set at an excitation wavelength of 270 nm with a 389 nm emission cut-off 
filter. The mobile phase consisted of an isocratic phase over 0 to 10 minutes of 0.1M sodium 
acetate pH 4.5 with 7% acetonitrile followed by a linear gradient of 7 to 45% acetonitrile for 
10 minutes, returning to initial conditions over two minutes and continued isocratically for 
eight minutes, with a total run time of 30 minutes and a flow rate of 1mL/minute. SAM and 
SAH levels were calculated as µmol per mg total protein. Levels of SAM, SAH and 
SAM/SAH ratio in drug treated cells were then calculated as a percentage of control, drug 
vehicle treated cells. 
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2.5  Global DNA methylation assay 
Measurement of global methylation of newly synthesised DNA was based on a method by 
Lambooy et al [24]. Briefly, cells were pulse labelled for 4 hours with 165 nM L-[methyl-3H] 
Methionine (Amersham Biosciences, Chalfont St.Giles, UK; 3.07 TBq/mmol) and 344 nM [2-
14C] Thymidine (Amersham Biosciences; 2.15 GBq/mmol). The DNA was extracted from 
5x106 cells, using a QIAamp DNA Mini Kit (QIAGEN Ltd, Crawley, UK) according to the 
manufacturer’s instructions. Purified DNA was eluted with 200 µL 10 mM Tris-HCl, 0.1 mM 
EDTA, pH 9.0 and radioactivity measured in a liquid scintillation counter. As SAM levels are 
affected by 6-MP, 6-TG and rMeMP, the global methylation results for these agents were 
calculated to take into account the differences in specific activity of SAM. The amount of 
endogenous SAM and radiolabelled methionine added to cells were calculated to be of similar 
concentrations per mg of cellular protein, hence the global methylation results were 
multiplied by the percentage decrease in endogenous SAM divided by 100 to correct for 
percentage change in specific activity of radiolabelled SAM derived from the radiolabelled 
methionine.  
 
2.6  DNMT activity 
The measurement of DNMT activity was based on a method by Fiala et al [30], with 
modifications. Cell pellets were lysed in 50 mM Tris/HCl pH 7.8, 1 mM EDTA, 10% 
glycerol, 1% Tween, 0.2 mM phenylmethylsulfonyl fluoride and 0.1 mg/mL (69U/mg) 
ribonuclease A by passing through a 25 1/4 gauge needle three times followed by three 
freeze/thaw (liquid nitrogen/ 37°C) cycles. Cell lysates containing 8 µg of protein were 
incubated with 1.5 µg (2.5 µl) poly(dI-dC)-poly(dI-dC) duplex (Amersham Biosciences) and 
1.9 µM, 111 kBq [Methyl-3H]-SAM (Amersham Biosciences; 2.89 TBq/mmol) in a total 
volume of 20 µL lysis buffer at 37°C for 4 hour. After stopping the reaction and adding 640 
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µL ice cold ethanol the DNA was allowed to precipitate overnight at -20°C. Digestion of the 
DNA was carried out as in the original method except that 20 units (4 µL) of DNase 1 with 20 
µL of DNase 1 buffer (100 mM Tris /HCl pH 7.5, 25 mM MgCl2, 5 mM CaCl2) was added 
prior to adding 4U (4 µL) of nuclease P1. Two units (2 µL) of alkaline phosphatase (Roche) 
were used. One hundred µL of sample were run using the same column type as for SAM/SAH 
analysis but maintained at 25oC, a Waters 996 PDA detector and Flow Scintillation Analyzer 
500TR Series (Perkin-Elmer, Beacons Field, UK). Standards of deoxyinosine (dI)(Sigma-
Aldrich) prepared in water were also run on the HPLC, to determine the fraction of dI in 
samples which became methylated by [Methyl-3H]-SAM, as a determinant of DNMT activity. 
The mobile phase consisted of an isocratic phase from 0 to 12 minutes of 25 mM sodium 
acetate, 12.5 mM sodium citrate, pH 5.1 with 8% methanol followed by a linear gradient of 8 
to 20% methanol for 3 minutes, held isocratically at 20% methanol for 5 minutes and 
returning to initial conditions over three minutes and continued isocratically for 7 minutes, 
with a total run time of 30 minutes and a flow rate of 1mL/minute. DNMT activity was 
calculated as pmol of 3H methyl groups transferred to deoxycytidine/µg dI and levels for drug 
treated cells quoted as a percentage of control, drug vehicle treated cells. 
 
2.7  Methylation status of CpG sites in MAGE1A promoter by pyrosequencing 
One µg of DNA, isolated from cell pellets using the QIAamp DNA Mini Kit (QIAGEN), was 
bisulphite-modified using the Epitect Bisulfite Kit (QIAGEN) and eluted into 40 µL TE 
buffer. The MAGE1A  region (-90/+209) was amplified using 5 µL modified template DNA, 
300 ng of each primer (TAGN, Gateshead, United Kingdom), 0.2 mM deoxynucleotide 
triphosphates (Applied Biosystems, Warrington, UK), and 2U FastStart Taq (Roche) in a total 
volume of 50 µL. Primers 5’-TTTTTATTTTTATTTAGGTAGGAT-3’ and 5’-Biotin-
TCTAAAAACAACCCAAACTAAAAC-3’, forward and reverse respectively, were used. 
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Pyrosequencing was performed using a PSQ 96MA Pyrosequencer (Biotage, Hertford, UK) 
and the sequencing primer 5’-TGTTGTTAGTTTTGGTTTAT-3’ according to the 
manufacturer’s protocol.  
 
2.8  Western Blotting 
Cells were lysed in RIPA buffer (50 mM Tris/HCl pH7.5, 150 mM NaCl, 1% Triton-X-100, 
0.5% sodium deoxycholate, 0.1%SDS) containing EDTA-free protease inhibitor cocktail 
(Roche) for 10 minutes on ice, vortexing for 3 seconds every minute. Debris was removed by 
centrifugation at 20800g at 4 oC for 10 minutes. Protein concentration of the cell lysate was 
quantified using the BCA kit (as described above), and lysates diluted with 2x Laemmli 
sample buffer (8% SDS, 40% glycerol, 20% 2-mercaptoethanol, 0.04% bromophenol blue 
and 0.25 M Tris HCl, pH 6.8). Twenty ug of lysate was separated on 4-12% Tris/Glycine gels 
(Invitrogen, Paisley, UK) and blotted onto polyvinylidene difluoride (BioRad, Hemel 
Hempstead, UK). Membranes were blocked for one hour in blocking buffer (100 mM Tris, 
pH 7.5, 0.9% NaCl, 0.05% Tween 20 and 5% non-fat dried milk) and probed with 1/2000 
dilution of rabbit polyclonal DNMT1 amino-terminal antibody (New England Biolabs, 
Hitchen, UK) in blocking buffer overnight at 4oC. After stripping the blots with 2% SDS in 
62.5 mM Tris buffer pH 6.7 for 30 minutes, at 50°C they were re-probed with 1/2000 dilution 
of mouse monoclonal vinculin antibody (Santa Cruz Biotechnology Inc., Heidelberg, 
Germany) for 1 hour, as a loading control. Visualisation was achieved using a 1/2000 dilution 
of HRP- conjugated goat anti-rabbit or goat anti-mouse antibody secondary antibodies in 
blocking buffer (Dako, Ely, UK) for 45 minutes at room temperature followed by enhanced 
chemiluminescence (Amersham) according to the manufacturer’s instructions and exposure to 
X-ray film. 
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2.9  Cell cycle 
Cells were harvested, washed in PBS and then fixed in 1 mL 70% ethanol:30% PBS and 
stored at 4°C for up to 1 month. For cell cycle analysis, cells were washed and then 
rehydrated in 1 mL PBS for 15 minutes at room temperature. Cells were pelleted and 
resuspended in PBS with 10% (v/v) 1 mg/mL RNAse and 10%(v/v) 0.4 mg/mL of propidium 
iodide and incubated for 30 minutes in the dark.  A single cell suspension was made by 
passing the cells through a 25-gauge needle. Cell cycle analysis was performed on a FACScan 
Flow Cytometer (Becton Dickinson, Warwickshire, UK) at an excitation wavelength of 488 
nm and fluorescence detection at 530nm using CellQuest Software  
 
2.10  Statistical analysis 
Experiments were performed using the parental EcR293 cells and the EcR293-TPMT/20 
derivative. Assay data were analysed with General Linear Models (GLM) with log10 drug 
dose, cell type (parental EcR293 cells or the EcR293-TPMT/20 derivative), inducer (MA or 
ethanol control) and independent repeat as independent factors using Systat version 10 (SPSS 
Inc, Chicago, IL). Each experiment was repeated independently on at least three occasions 
and each of these repeats (with samples in duplicate at each point) was coded as a factor in the 
analysis to take account of experimental variation between repeats. In the GLM, interaction 
between cell type and TPMT induction status was also included as an effect, and hypothesis 
tests used to compare effects of TPMT induction on the response by EcR293-TPMT/20 cells 
when TPMT induction and interaction terms were significant. A GLM was also used to 
analyse pyrosequencing data, with drug type (5-AdC, 6-TG, 6-MP), drug treatment (drug or 
vehicle control), TPMT status, and CpG island as main effects, and with drug treatment * 
CpG island, drug type * drug treatment, TPMT status * drug type, TPMT status * drug 
treatment, and drug type * drug treatment * TPMT as interaction terms. 
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3  Results 
3.1  MeTIMP levels after exposure of cells to 6-MP and rMeMP. 
To determine doses of 6-MP and rMeMP which produced comparable amounts of MeTIMP, 
the levels of MeTIMP produced after exposure of EcR293-TPMT/20 cells, with and without 
induction of TPMT expression, to these agents were measured (Fig. 2). In response to rMeMP 
the MeTIMP levels increased, producing 10-14 nmol MeTIMP/mg cellular protein at doses of 
4-16 µM rMeMP (Fig.2A); there was no significant difference in MeTIMP levels between 
EcR293-TPMT/20 cells with or without induction of TPMT expression (F1,33=1.46, P=0.23) 
and this is consistent with the production of MeTIMP by adenosine kinase and not TPMT (see 
Fig. 1). In contrast, after treatment with 6-MP, cells induced to express TPMT produced 
increased levels of MeTIMP (F1,21=27.3, P<0.00004; Fig 2B); MeTIMP levels increased to a 
plateau of 4 nmol MeTIMP/mg cellular protein at 6-MP doses >20 µM in the absence of 
TPMT induction but to 12 nmol MeTIMP/mg cellular protein at the same 6-MP doses after 
induction of TPMT expression. Thus, under conditions of TPMT induction, 0.5 – 16 µM 
rMeMP and 1.8 – 80 µM 6-MP produced comparable levels of MeTIMP. 
 
3.2  The effect of TPMT induction on drug-induced changes in SAM and SAH levels 
The effect of TPMT expression on the level of SAM and SAH levels and the SAM/SAH ratio 
after exposure of EcR293-TPMT/20 cells to 6-MP, rMeMP or 6-TG for 48 hours is shown in 
Fig. 3. After 6-MP treatment, EcR293-TPMT/20 cells, induced to produce TPMT, showed a 
statistically- significant increase in SAH compared to cells without TPMT induction. At doses 
of 1.8 to 80 µM, SAH increased 1.2 to 1.9 fold, respectively (F1,38= 23.68, P<0.0001; Fig. 
3A). The inducing agent, MA, had no significant effect on SAH levels in parental EcR293 
cells exposed to 6-MP (F1,38= 0.024, P>0.8), data not shown.  
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To determine if the increase in SAH with 6-MP in high TPMT-expressing cells was caused by 
the 6-MP metabolite MeTIMP, parental EcR293 cells and EcR293-TPMT/20 cells were 
treated with rMeMP, which is converted directly to MeTIMP intracellularly (Fig. 1). The 
amount of rMeMP used in these assays (4-16µM) was chosen to produced similar amounts of 
MeTIMP as formed with exposure of cells to 6-MP (Fig. 2) in TPMT-induced cells. There 
were no dose effects of rMeMP on SAH levels (Fig 3A, F1,29= 0.019, P>0.893) and no effect 
of TPMT induction (F1,29= 0.307, P>0.58).  
As with exposure to 6-MP, TPMT induction significantly increased SAH levels in response to 
6-TG (Hypothesis test; F1,57= 9.8, P=0.003), but the effect was small compared to the TPMT-
induced increase in SAH levels obtained with 6-MP (Fig. 3A). There was no effect of the 
inducing agent, MA, on SAH levels in parental EcR293 cells treated with 6-TG (F1,57= 0.03, 
P=0.863), data not shown. With respect to SAM levels (Fig. 3B), there was no effect of 
TPMT induction in response to 6-MP (F1,39=0.157, P=0.694) or rMeMP (F1,41=1.4, P=0.24). 
However, TPMT expression reduced the extent of SAM depletion in response to 6-TG 
(Hypothesis test for EcR293-TPMT/20 cells, F1,57= 8.251 P=0.006). In contrast to the 
apparent lack of effect of TPMT induction on SAM levels in EcR293-TPMT/20 cells treated 
with rMeMP, the addition of MA significantly reduced the extent of SAM depletion in 
rMeMP-treated parental EcR293 cells (F1,29=40.2, P=0.000001). This implies that MA 
affected the response to rMeMP which was counteracted by TPMT induction in the EcR293-
TPMT/20 cells. 
The changes in SAM and SAH levels in these experiments were reflected in the SAM/SAH 
ratio (Fig. 3C). For 6-MP, the increased SAH levels while SAM remained unchanged resulted 
in a decreased SAM/SAH ratio in response to TPMT induction. With 6-TG there was no 
overall effect of TPMT on SAM/SAH ratio since reduction in depletion of SAM and elevation 
of SAH occurred in response to TPMT induction. 
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3.3  The effect of TPMT induction on drug induced changes in global DNA methylation 
The effects of 6-MP, 6-TG and rMeMP on global DNA methylation in EcR293-TPMT/20 
cells, corrected for the effects of TPMT induction on SAM levels, are shown in Fig. 4A. 6-
MP and 6-TG inhibited the methylation of newly-synthesised DNA in a dose-dependent 
manner, but there was no statistically significant dose effect of rMeMP (F1,13=1.127, 
P=0.308). 
The induction of TPMT had no significant effect on inhibition of DNA methylation induced 
by treatment with 6-MP (F1,51=1.91, P=0.17). The extent of inhibition of DNA methylation in 
response to rMeMP was significantly increased after induction of TPMT (F1,13=9.77, P=0.008. 
However, MA significantly decreased the extent of inhibition of DNA methylation in 
response to rMeMP in parental EcR293 cells (F1,13=20.7, P=0.00055). As was found with the 
SAM measurements and rMeMP treatment, MA appears to affect the response of global 
methylation to rMeMP which is counteracted by TPMT induction in the EcR293-TPMT/20 
cells. The induction of TPMT expression with MA significantly decreased the extent of 
inhibition of DNA methylation in response to increasing doses of 6-TG relative to un-induced 
cells (F1,61=28.6, P<0.0001). 
As a positive control for effects on DNA methylation, cells were also treated with 5-AdC. The 
reduction in DNA methylation with increasing dose of 6-MP, rMeMP and 6-TG when TPMT 
expression was low was comparable to that observed with 5-AdC. For 5-AdC, induction of 
TPMT with MA had a small but statistically-significant effect on increasing the extent of de-
methylation, but there was no effect of MA on the parental cells (data not shown).  
 
3.4  The effect of 6-TG, 6-MP, rMeMP and 5-AdC on gene specific DNA methylation 
Patterns of gene-specific methylation vary between cell types but since the MAGE1A gene is 
methylated in normal tissues [31] and is demethylated by dAdC [32] this gene is a good candidate 
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for studying the effects of the thiopurine drugs on gene-specific methylation in a line derived from 
normal embryonic cells. To study the effects of 6-MP, 6-TG and 5-AdC on the methylation of 
MAGE1A, methylation at three CpG sites in the promoter was measured in EcR293-TPMT/20 cells 
expressing low and high TPMT (Table 1). For this experiment, the concentration of each drug used 
was the dose showing the maximum decrease of global DNA methylation and DNMT activity (Fig. 
4A and 4B) at the start of the plateau where further increase in dose did not cause a significantly-
greater decrease in DNA methylation and DNMT activity. In the analysis by GLM, the three CpG 
sites differed in the extent of demethylation in response to drug and was taken into account by 
including this effect in the analysis; there was no differential effect of TPMT between CpG sites 
(P=0.36). There was a significant decrease in CpG- site methylation in response to drug treatment 
(F1,92=42.3; P<0.00001), but this varied depending on drug type: treatment with 5-AdC produced a 
marked decrease in methylation from 67.5% to 43% (averaged across the 3 CpG sites,least-squares 
means; Hypothesis test: F1,94=368; P<0.0001); conversely, treatment with 6-TG or 6-MP did not 
decrease methylation, but instead gave evidence of slightly increased methylation from 67% to 
72% (Hypothesis tests: F1,94>12; P<0.001). Overall, TPMT had no statistically-significant effect on 
methylation (TPMT main effect: F1,92=1.7; P=0.193).  
 
3.5  The effect of 6-TG, 6-MP, rMeMP and 5-AdC on DNMT levels 
The effect of TPMT on DNMT activity after 48 hour exposure of EcR293-TPMT/20 cells to 
drug is shown in Fig. 4B. The inhibition of DNMT activity largely reflected the changes in 
global DNA methylation obtained with each drug. For 6-MP, rMeMP and 5-AdC there was no 
difference in magnitude of DNMT activity between low and high TPMT-expressing cells 
(F1,19≤2.65, P>0.119) however, after 6-TG treatment cells expressing high TPMT showed a 
statistically-significant elevation in DNMT activity (F1,25=18.86, P=0.0002). The effect of 6-
TG, 6-MP, rMeMP and 5-AdC on expression of soluble DNMT1 protein is shown in Fig. 5A. 
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All drugs decreased DNMT1 protein expression and this reflected the changes in the DNMT 
activity.   
To determine whether changes in global methylation and DNMT activity related to extent of 
drug-induced growth inhibition, the effects of equitoxic doses (EC50) of 6-MP and 6-TG, for 
high and low TPMT expression, on global methylation and DNMT activity were compared. 
These drugs are cytostatic and did not cause apoptosis at time points studied; therefore, EC50 
values represent inhibition of proliferation by 50%. For 6-MP, equivalent growth inhibition 
with low and high TPMT expression showed statistically-different levels of global DNA 
methylation and DNMT activity (Fig. 5B), suggesting that inhibition of global DNA 
methylation and DNMT activity were not directly related to growth inhibition. Similar levels 
of global DNA methylation and DNMT activity were observed at equitoxic doses of 6-TG for 
high and low TPMT expression. 
It has been reported that DNMT levels and global methylation alter during different phases of 
the cell cycle [32]. Hence, the effects of 6-MP and 6-TG on the fraction of cells in G1, S and 
G2 phases were measured to determine if changes in DNMT activity could be related to 
changes in the cell cycle. Both 6-MP and 6-TG appeared to cause S-phase arrest with a 
concomitant decrease of cells in the G2 phase, in TPMT un-induced cells (Fig. 5C). However, 
this did not quite reach statistical significance when compared to TPMT un-induced control 
(non-drug treated) cells (fraction of cells in G2; 8 µM 6-MP P=0.07, 2.8 µM 6-TG P=0.08). 
As DNMT and DNA methylation have been shown to peak in the S phase, 6-MP- and 6-TG-
induced changes in the cell cycle are unlikely to be responsible for the 6-MP- and 6-TG-
induced decrease in DNMT and global DNA methylation.  
4  Discussion 
We originally postulated that TPMT levels would differentially affect global DNA 
methylation changes mediated by 6-MP and 6-TG. This hypothesis was based on the 
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knowledge that TPMT metabolises 6-MP to MeTIMP, a strong inhibitor of DNPS, which 
decreases ATP and leads to a concomitant reduction in SAM levels [22]. Utilisation of SAM 
by TPMT-mediated metabolism of the thiopurine drugs has also been postulated to contribute 
to reduction in SAM with increased SAH levels in the T-ALL cell line Molt-4 [23]. As SAM 
is required as a substrate for DNA methylation by DNMTs, increased cellular TPMT would 
be expected to be associated with a greater decrease in global DNA methylation on exposure 
of cells to 6-MP. However, this was not the case in the studies presented here. Global DNA 
methylation of EcR293-TPMT/20 cells was inhibited by 6-MP to a similar extent in 
conditions of low and high TPMT expression. Also, as 6-TG is not metabolised to MeTIMP, 
but to MeTGMP, a weak inhibitor of DNPS in contrast to MeTIMP [27], this drug would be 
expected to have less effect on DNA methylation than 6-MP. This was only the case in high 
TPMT expressing cells, as 6-TG in low TPMT expressing cells inhibited DNA methylation to 
a similar extent to 6-MP, at equivalent drug doses. These results suggest that a non-TPMT 
metabolised metabolite of 6-MP and 6-TG, possibly thioguanine nucleotide (TGN), 
contributes to a decrease in global DNA methylation, as illustrated in Fig. 6. 
Interestingly, induction of TPMT increased the extent of global DNA de-methylation with 5-
AdC. It is possible that there is increased utilisation of SAM by increased levels of TPMT 
resulting in decreased SAM available for methylation of 5-AdC incorporated into DNA by 
DNMTs. Although MA, used in the induction of TPMT, was originally thought to have no 
effects on mammalian cells and the expression of methyltransferases is apparently not 
affected by MA (M. Zornig, personal communication), it has been reported that cytokine 
signalling in a murine pre-B cell line and the expression of apoptosis-related genes in a 
human colon carcinoma cell line can be affected by MA [33, 34]. We found that MA reduced 
the extent of SAM depletion and global DNA methylation by rMeMP in the parental EcR293 
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cells. However, this was not apparent in the EcR293-TPMT/20 cells, in which these effects 
were reversed by TPMT induction. The mechanism for these effects is unclear.  
For both 6-MP and 6-TG, SAH levels were increased in response to TPMT induction, as 
would be expected if higher TPMT levels increased the methyl transfer rate from SAM. 
However, this was not reflected by changes in SAM levels, implying that the production of 
SAM was not rate-limiting. The increase in SAH observed when TPMT was induced was 
greater with 6-MP than with 6-TG, possibly due to increased utilisation of SAM in the 
production of methylated metabolites of 6-MP, or because a metabolite of 6-MP is inhibiting 
the breakdown of SAH. However, increase in SAH was not associated with MeTIMP levels 
per se, as equivalent levels of MeTIMP produced on exposure of cells to rMeMP, compared 
to 6-MP, were not associated with increased SAH.  
Several studies have shown that alterations in the ratio of SAM to SAH, rather than SAM or 
SAH levels alone relate to changes in DNA methylation [12-14], as SAH has an inhibitory 
affect on DNMT activity[15]. With 6-TG there was a statistically-significant difference in 
global DNA methylation in the presence of induced compared to uninduced TPMT, which 
was not reflected by a difference in the SAM/SAH ratio. Also, in comparison to 6-MP and 
rMeMP, 6-TG with low TPMT reduced the SAM/SAH ratio to a lesser extent but DNA 
methylation to a similar extent. This suggests that factors other than SAM/SAH levels 
influence methylation, particularly with 6-TG. This led to the investigation of the effect of 
these drugs on DNMT activity.  
As changes in DNA methylation were mirrored by changes in DNMT activity, for all drugs 
studied, inhibition of this enzyme is likely to play a major role in reduction of DNA 
methylation. The decrease in DNMT activity was also associated with a decrease in soluble 
DNMT1 protein expression. The mechanism by which 6-TG decreases DNMT levels is 
unclear, but is more prominent with non-TPMT related metabolism, as low TPMT levels were 
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associated with significantly greater inhibition of DNMT activity. Unlike 6-TG, 6-MP 
showed an equivalent inhibition of global DNA methylation and DNMT activity under 
conditions of low and induced TPMT expression. When TPMT is induced this inhibition is 
likely to be due to the 6-MP metabolite MeTIMP, as exposure of cells to rMeMP also resulted 
in a significant decrease in global DNA methylation and DNMT activity and protein 
expression. 
During the cell cycle, DNMT1 expression is significantly reduced in the G0- and G1- phases 
and peaks during S-phase (reviewed in [35]). The thiopurine induced reduction in global 
DNA methylation and DNMT levels was not associated with statistically-significant changes 
in the cell cycle phases or with the observed trend for an increase in the fraction of cells in S-
phase and decrease of cells in G2. This suggests that inhibition of DNMT by 6-TG and 6-MP 
is not due to changes in the fraction of cells in specific cell-cycle phases.  
Although 6-TG and 6-MP produced changes in global demethylation, it is not clear if this is 
also reflected at the level of individual genes. In contrast to global demethylation, decrease in 
methylation of the MAGE1A promoter was detected with 5-AdC but not with the thiopurine 
drugs. However, single-gene analyses require a longer-term exposure to drug than the global 
methylation assays. Since 6-TG and 6-MP cause extensive cell kill after long term exposure at 
the concentrations necessary to observe a decrease in global DNA methylation, this will 
mitigate against identifying changes in methylation status of individual genes. Furthermore, 
5-AdC caused a greater decrease in DNMT activity and DNMT1 protein levels than 6-MP 
and 6-TG. The biological significance of the apparent slight increase in methylation at the 
MAGE1A locus in response to 6-TG or 6-MP is not clear, but may relate to the properties of 
surviving cells resistant to the drug treatment.  
These results do not negate the possibility of gene specific demethylation effects at other 
genetic loci in cancer cells by the thiopurine drugs. It has been reported that DNMT1 and 
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DNMT3b cooperate to silence genes and that knockout of both these genes results in a 
significantly greater reduction in methylated cytosines compared to the additive effect of 
knocking out each DNMT alone [36] and this substantial loss of methylation occurs in the 
promoter regions of tumour suppressor genes in cancer cell lines [37]. It has also been 
reported that DNMT3b may play a compensatory role in maintaining methylation patterns 
[36], which is possibly cell type dependent [38]. As 5-AdC has been shown to form DNMT3-
DNA adducts to a similar extent to DNMT1-DNA adducts [39], this may contribute to the 
demethylating effect of 5-AdC at the MAGE1A promoter. It is unknown if the thiopurines 
affect DNMT3b expression in these cells as the endogenous levels were too low to be 
detected using three commercially available antibodies (Hogarth and Coulthard, unpublished 
data).  
It is important to note that DNMT1 knockdown causes effects which are independent of DNA 
methylation and histone deacetylation, including induction of genes involved in cell cycle 
arrest and stress response and that these effects may have important therapeutic implications 
[40]. These authors point out that inhibition of DNA methylation can induce genes that 
promote metastasis and cause unwanted side effects and therefore targeting methylation-
independent effects of DNMT1 may be therapeutically advantageous. Further investigations 
are required to determine if the thiopurines mediate methylation-dependent and/or 
methylation-independent effects of DNMT inhibition. 
In summary, we have shown that 6-MP and 6-TG, at concentrations shown to be achievable 
in the plasma of patients administered these drugs [41-43], cause inhibition of global DNA 
methylation and that the extent of this inhibition is influenced by TPMT for 6-TG, but not for 
6-MP. Although it has been suggested that inhibition of global DNA methylation by 6-MP is 
due to changes in SAM and SAH levels [23, 24] our results suggest that a reduction in DNMT 
activity, in association with decreased DNMT1 protein levels, also has a prominent role for 
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both 6-MP and 6-TG. These observations should be confirmed using in vivo leukaemic 
models as there are insufficient blast cells to be able to determine methylation changes in 
patients treated with thiopurines during remission. As demethylating agents are known to be 
active in leukaemia [9, 10], it is possible that inhibition of DNA methylation by the thiopurine 
drugs may also contribute to their cytotoxic affects. 
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Table 1. Comparison of the effect of 6-MP, 6-TG and 5-AdC on the percentage methylation of 3 
CpG sites of the MAGE1A promoter. Low and high TPMT expressing EcR293-TPMT/20 cells 
were exposed to 6-MP, 6-TG, 5-AdC or drug control vehicle (CV) for 6 doubling times, replacing 
with fresh drug and TPMT inducing agent (MA, ■ ) or MA control vehicle (ethanol, □) after 3 
doubling times. In vitro methylated DNA (IVM) and human whole blood DNA (N) were used as 
controls for each experiment. The mean and SD of 3 individual measurements, of percentage 
methylation of each CpG site, for each treatment is shown. 
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Fig. 1. Metabolism of 6-MP and 6-TG in human ALL cells. PRPP, 5’-phosphoribosyl-1-
pyrophosphate; GMPS guanosine monophosphate synthase; HGPRT, hypoxanthine guanine 
phosphoribosyltransferase; IMPD, inosine monophosphate dehydrogenase; SAM, S-
adenosine methionine; TPMT, thiopurine methyltransferase; AO, aldehyde oxidase; 8-OHTG, 
8-hydroxythioguanine; XO, xanthine oxidase; TGN, thioguanine nucleotides; TIMP, 
thioinosine 5’-monophosphate; TXMP, thioxanthine monophosphate; TGMP, thioguanosine 
monophosphate; MeTG, methylthioguanine; MeMP, methylmercaptopurine; rMeMP, 
methylmercaptopurine riboside; AK, adenosine kinase 
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Fig. 2. The levels of MeTIMP after 48 hr exposure of EcR293-TPMT/20 cells to rMeMP (A) 
and 6-MP (B), with low (○) and high TPMT (●) expression. Error bars represent the S.D. 
from three separate experiments 
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Fig. 3.The effect of low (○) compared with high TPMT (●) expression on SAM (A) and SAH 
(B) levels and the SAM/SAH ratio (C) after 48 hr exposure of EcR293-TPMT/20 cells to 6-
TG, 6-MP and rMeMP. Error bars represent the S.D. of duplicates from three separate 
experiments. Inset graphs show where there is a significant effect of TPMT induction (P 
<0.05) on global methylation with exposure to drug (see text for details). The points are the 
least-squares means +/- SE from GLM analysis. Ordinate: global methylation (% control); 
abscissa: TPMT induction (1) or no TPMT induction (0, ethanol control). 
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Fig. 4. The effect of low (○) compared with high TPMT (●) expression on global DNA 
methylation (A) and DNMT activity (B) after 48 hr exposure of EcR293-TPMT/20 cells to 6-
TG, 6-MP, rMeMP and 5-AdC. Error bars represent the S.D. of duplicates from three separate 
experiments for DNMT activity and at least 3 separate experiments for global DNA 
methylation. 
Inset graphs show where there is a significant effect of TPMT induction (P <0.05) on global 
methylation with exposure to drug (see text for details). The points are the least-squares 
means +/- SE from GLM analysis. Ordinate: global methylation (% control); abscissa: TPMT 
induction (1) or no TPMT induction (0, ethanol control). 
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Fig. 5. Western blots showing the effect of low compared with high TPMT expression on 
DNMT1 protein expression after 48 hr exposure of EcR293-TPMT/20 cells to 6-TG, 6-MP, 
rMeMP and 5-AdC (A). The effect of equitoxic 6-MP and 6-TG doses on global DNA 
methylation, DNMT activity (B) and cell cycle (C) in TPMT low (□) and TPMT high (■) 
expressing EcR293-TPMT/20 cells. Error bars represent the mean +S.D. from 3 separate 
experiments for DNMT activity (* p<0.05, comparing EC50 6-MP doses) and at least 3 
separate experiments for global DNA methylation (*** p < 0.001, comparing EC50 6-MP 
doses). Cell cycle graph shows cells in G1 (dark grey bar), S (white bar) and G2 (light grey 
bar). 
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Fig. 6
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Fig. 6. Hypothesis for inhibition of DNA methylation by 6-MP and 6-TG in relation to TPMT 
status.  
 
